Monalizumab

Monalizumab (formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies and other cancers. Monalizumab (formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies and other cancers. Monalizumab is a monoclonal antibody targeted at NKG2A. It is a checkpoint inhibitor.